Pay in 4 interest-free payments of $7.22 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
GLP-1 and dual-agonist breakthroughs in metabolic disease
The serial cultivation of human diploid cell strains
491 Patients who received 200 mg of mirikizumab subcutaneously every 4 or 12 weeks presented a significant downward trend in the expression of genes encoding inflammatory mediators, such as cytokines and chemokines
Common side effects in clinical use are mild and localized
Where available, endotoxin testing results are included in the batch documentation
J Biol Chem 280(31):2849828506 Villard E, Perret C, Gary F, Proust C, Dilanian G, Hengstenberg C, Ruppert V, Arbustini E, Wichter T, Germain M, Dubourg O, Tavazzi L, Aumont MC, DeGroote P, Fauchier L, Trochu JN, Gibelin P, Aupetit JF, Stark K, Erdmann J, Hetzer R, Roberts AM, Barton PJ, Regitz-Zagrosek V, Aslam U, Duboscq-Bidot L, Meyborg M, Maisch B, Madeira H, Waldenstrm A, Galve E, Cleland JG, Dorent R, Roizes G, Zeller T, Blankenberg S, Goodall AH, Cook S, Tregouet DA, Tiret L, Isnard R, Komajda M, Charron P, Cambien F (2011) A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy
